Evolent Health, Inc. (EVH)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore ≥ 3 before any bullish entry.
Company overview
Evolent Health, Inc. provides clinical and administrative solutions to healthcare payers and providers in the U.S. through its subsidiary, Evolent Health LLC. The company operates in two segments: Evolent Health Services, which offers a platform for health plan management and population health oversight, and Clinical Solutions, which focuses on care management services for specialty care delivery. Founded in 2011, it is headquartered in Arlington, Virginia.
Fundamental
weakEvolent Health faces significant leverage and profitability challenges, with weak coverage metrics and a distressed Altman Z-score.
Revenue has reaccelerated in 2026 after a contract-driven 2025 decline, but EVH is still loss-making on a GAAP basis with weak coverage metrics. The stock looks inexpensive on EV/Sales (~0.66x) yet carries heavy leverage and a distressed Altman Z-score, so the thesis hinges on executing a profitability/margin recovery while maintaining key partner relationships and navigating regulation.
Sentiment
fairRecent sentiment shows improvement post-earnings, but broader concerns about leverage and profitability persist.
Near-term narrative is dominated by the 2026-08-06 Q2 results / outlook update (announced), with the limited last-14d coverage skewing positive. Baseline coverage (30–90d) leaned slightly negative on leverage/Medicaid-headwind concerns, so the sentiment delta appears improved but remains low-confidence due to sparse recent articles; legal/regulatory scans showed no regulator-confirmed investigation overhang.
Technical
fairThe stock has seen a short-term rally but remains below key moving averages, indicating an unconfirmed bullish trend.
EVH has repaired its short-term trend after the 8/6 washout, reclaiming EMA9/21, SMA20, SMA200 and daily VWAP with RSI14 at 56.96 and a positive MACD histogram. The read is still mixed because price is just below SMA50, MACD line remains below zero, and Williams %R at -3.35 signals the rebound is already near short-term overbought.
You’re looking at 2026-08-16 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.